ProPhase Labs (NASDAQ:PRPH) Releases Earnings Results, Misses Expectations By $0.21 EPS

ProPhase Labs (NASDAQ:PRPH) released its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.21), Fidelity Earnings reports. ProPhase Labs had a negative net margin of 12.92% and a negative return on equity of 15.95%.

Shares of NASDAQ:PRPH traded down $0.45 during midday trading on Thursday, hitting $6.94. 2,843 shares of the stock were exchanged, compared to its average volume of 350,412. The company has a debt-to-equity ratio of 0.93, a current ratio of 8.35 and a quick ratio of 7.35. ProPhase Labs has a 52-week low of $1.20 and a 52-week high of $16.04. The business’s fifty day simple moving average is $7.98 and its two-hundred day simple moving average is $8.58.

PRPH has been the subject of a number of research analyst reports. TheStreet upgraded ProPhase Labs from a “d+” rating to a “c” rating in a report on Wednesday, February 3rd. Dawson James initiated coverage on ProPhase Labs in a report on Wednesday, January 20th. They issued a “buy” rating and a $25.00 target price for the company.

About ProPhase Labs

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand.

Further Reading: How does a margin account work?

Earnings History for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.